SQZ Biotechnologies to Present at Jefferies Healthcare Conference
02 6월 2022 - 5:45AM
Business Wire
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full
potential of cell therapies for multiple therapeutic areas, today
announced that Armon Sharei, Ph.D., Chief Executive Officer and
Founder of SQZ Biotechnologies, will present at the Jefferies
Healthcare Conference on June 8, in New York, NY. Presentation time
and webcast information is available below.
PRESENTATION DETAILS
Wednesday, June 8 Jefferies Healthcare Conference
2:30-2:55 p.m. ET Webcast
Conference webcast details and the company’s most recent
corporate overview presentation will be available on the Investors
section of the SQZ website. Replay will be available for 90
days.
Based on guidance from the SEC, investors should note that the
company may announce future healthcare conference presentations on
the Events & Presentations page of the Investor Relations
section of its corporate website, investors.sqzbiotech.com. It is
possible that the information posted there could be deemed to be
material information.
About SQZ Biotechnologies
SQZ Biotechnologies Company is a clinical-stage biotechnology
company focused on unlocking the full potential of cell therapies
for patients around the world. The company has active programs in
oncology, autoimmune and infectious diseases, as well as additional
exploratory initiatives to support future pipeline growth. SQZ’s
proprietary Cell Squeeze® technology can deliver multiple
biological materials into many cell types, offering the ability to
engineer a broad range of potential therapeutics. With clinical
production timelines already under 24 hours, the company has the
potential to enable broader patient accessibility through
point-of-care manufacturing implementation across multiple
therapeutic programs. Our approach could also improve a patient’s
treatment journey with no planned hospitalization or
preconditioning treatment. The company’s first therapeutic efforts
seek to generate target-specific immune responses, both through
activation for the treatment of solid tumors and infectious
diseases, and by immune tolerance for the treatment of autoimmune
diseases. For more information, please visit
www.sqzbiotech.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220601006003/en/
Investor: Mike Kaiser michael.kaiser@sqzbiotech.com
857-760-0398
Media: John Lacey john.lacey@sqzbiotech.com
781-392-5514
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024